{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:55:17Z","timestamp":1790834117666,"version":"4.1.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 study evaluating the feasibility of 4 cycles of blinatumomab administered every 3 months during the first year after HCT in an effort to mitigate relapse in high-risk ALL patients. Twenty-one of 23 enrolled patients received at least 1 cycle of blinatumomab and were included in the analysis. The median time from HCT to the first cycle of blinatumomab was 78 days (range, 44 to 105). Twelve patients (57%) completed all 4 treatment cycles. Neutropenia was the only grade 4 adverse event (19%). Rates of cytokine release (5% G1) and neurotoxicity (5% G2) were minimal. The cumulative incidence of acute graft-versus-host disease (GVHD) grades 2 to 4 and 3 to 4 were 33% and 5%, respectively; 2 cases of mild (10%) and 1 case of moderate (5%) chronic GVHD were noted. With a median follow-up of 14.3 months, the 1-year overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) rates were 85%, 71%, and 0%, respectively. In a matched analysis with a contemporary cohort of 57 patients, we found no significant difference between groups regarding blinatumomab\u2019s efficacy. Correlative studies of baseline and posttreatment samples identified patients with specific T-cell profiles as \u201cresponders\u201d or \u201cnonresponders\u201d to therapy. Responders had higher proportions of effector memory CD8 T-cell subsets. Nonresponders were T-cell deficient and expressed more inhibitory checkpoint molecules, including T-cell immunoglobulin and mucin domain 3 (TIM3). We found that blinatumomab postallogeneic HCT is feasible, and its benefit is dependent on the immune milieu at time of treatment. This paper is posted on ClinicalTrials.gov, study ID: NCT02807883.<\/jats:p>","DOI":"10.1182\/blood.2021013290","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T21:00:35Z","timestamp":1639688435000},"page":"1908-1919","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"139","author":[{"given":"Mahmoud R.","family":"Gaballa","sequence":"first","affiliation":[{"name":"Bone Marrow Transplant and Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Den\u00e1i R.","family":"Milton","sequence":"additional","affiliation":[{"name":"Department of Biostatistics;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1697-8575","authenticated-orcid":false,"given":"Xianli","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics & Computational Biology; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ganesh","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-608X","authenticated-orcid":false,"given":"Sajad","family":"Khazal","sequence":"additional","affiliation":[{"name":"Department of Pediatric Stem Cell Transplantation & Cellular Therapy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Nandivada","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjida","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0079-8617","authenticated-orcid":false,"given":"Mecit","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Daher","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafet","family":"Basar","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohtesh","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheath","family":"Alatrash","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2224","authenticated-orcid":false,"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-0355","authenticated-orcid":false,"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Tewari","sequence":"additional","affiliation":[{"name":"Department of Pediatric Stem Cell Transplantation & Cellular Therapy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-5279","authenticated-orcid":false,"given":"Ken","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics & Computational Biology; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation & Cellular Therapy, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2022032421390083100_B1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood."},{"issue":"19","key":"2022032421390083100_B2","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","article-title":"Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood."},{"issue":"9","key":"2022032421390083100_B3","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood."},{"issue":"4","key":"2022032421390083100_B4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clml.2014.01.002","article-title":"The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Zhou","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2022032421390083100_B5","first-page":"421723","article-title":"Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"2014","author":"Bar","year":"2014","journal-title":"Leukemia Res Treat."},{"issue":"2","key":"2022032421390083100_B6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood."},{"issue":"5","key":"2022032421390083100_B7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.hoc.2009.07.001","article-title":"Cytogenetics and molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Mr\u00f3zek","year":"2009","journal-title":"Hematol Oncol Clin North Am."},{"issue":"4","key":"2022032421390083100_B8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4103\/sajc.sajc_13_18","article-title":"Impact of cytogenetics on outcomes in pediatric acute lymphoblastic leukemia","volume":"7","author":"Chennamaneni","year":"2018","journal-title":"South Asian J Cancer."},{"issue":"5","key":"2022032421390083100_B9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2019.220756","article-title":"Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research","volume":"105","author":"Lazaryan","year":"2020","journal-title":"Haematologica."},{"issue":"7","key":"2022032421390083100_B10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Poon","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2022032421390083100_B11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/bmt.2012.195","article-title":"Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia","volume":"48","author":"Poon","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"2022032421390083100_B12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022032421390083100_B13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol."},{"issue":"13","key":"2022032421390083100_B14","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM198903303201303","article-title":"Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms","volume":"320","author":"Sullivan","year":"1989","journal-title":"N Engl J Med."},{"issue":"6","key":"2022032421390083100_B15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbmt.2017.02.012","article-title":"Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow Donor Program","volume":"23","author":"Miyamoto","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2022032421390083100_B16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.bmt.1701064","article-title":"Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia","volume":"21","author":"Passweg","year":"1998","journal-title":"Bone Marrow Transplant."},{"issue":"21","key":"2022032421390083100_B17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V124.21.379.379","article-title":"BLAST: a confirmatory, single-arm, phase 2 tudy of blinatumomab, a Bispecific T-Cell Engager (BiTE\u00ae) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)","volume":"124","author":"Goekbuget","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2022032421390083100_B18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"issue":"36","key":"2022032421390083100_B19","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022032421390083100_B20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"issue":"8","key":"2022032421390083100_B21","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2022032421390083100_B22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood."},{"key":"2022032421390083100_B23","article-title":"Blincyto (blinatumomab). U.S. Food and Drug Administration website","author":"Amgen Inc","year":"2018"},{"issue":"6","key":"2022032421390083100_B24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nbt.2594","article-title":"viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia","volume":"31","author":"Amir","year":"2013","journal-title":"Nat Biotechnol."},{"key":"2022032421390083100_B25","first-page":"3221","article-title":"Accelerating t-SNE using tree-based algorithms","volume":"15","author":"van der Maaten","year":"2014","journal-title":"J Mach Learn."},{"issue":"1","key":"2022032421390083100_B26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell."},{"key":"2022032421390083100_B27","article-title":"Pre-HCT preparative regimen (conditioning)","author":"CIBMTR","year":"2020"},{"issue":"6","key":"2022032421390083100_B28","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2022032421390083100_B29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood."},{"issue":"3","key":"2022032421390083100_B30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat."},{"issue":"2","key":"2022032421390083100_B31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ni1554","article-title":"CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator","volume":"9","author":"Cai","year":"2008","journal-title":"Nat Immunol."},{"key":"2022032421390083100_B32","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3389\/fimmu.2020.02188","article-title":"CD160 plays a protective role during chronic infection by enhancing both functionalities and proliferative capacity of CD8+ T cells","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol."},{"issue":"10","key":"2022032421390083100_B33","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia."},{"issue":"22","key":"2022032421390083100_B34","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2021011822","article-title":"Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab","volume":"138","author":"Puzzolo","year":"2021","journal-title":"Blood."},{"issue":"1","key":"2022032421390083100_B35","doi-asserted-by":"crossref","first-page":"e21105","DOI":"10.1002\/cnr2.1105","article-title":"Targeting regulatory T cells for improving cancer therapy: challenges and prospects","volume":"1","author":"Dwarakanath","year":"2018","journal-title":"Cancer Rep (Hoboken)."},{"issue":"1","key":"2022032421390083100_B36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/1078-0432.CCR-18-1211","article-title":"Preventing Lck activation in CAR T cells confers Treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in nonlymphodepleted hosts","volume":"25","author":"Suryadevara","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2022032421390083100_B37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.1006","article-title":"Blinatumomab pharmacodynamics and exposure-response relationships in relapsed\/refractory acute lymphoblastic leukemia","volume":"58","author":"Zhu","year":"2018","journal-title":"J Clin Pharmacol."},{"issue":"9","key":"2022032421390083100_B38","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"2022032421390083100_B39","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nri2970","article-title":"Harnessing the biology of IL-7 for therapeutic application","volume":"11","author":"Mackall","year":"2011","journal-title":"Nat Rev Immunol."},{"issue":"24","key":"2022032421390083100_B40","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2012-06-437236","article-title":"Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation","volume":"120","author":"Perales","year":"2012","journal-title":"Blood."},{"issue":"47","key":"2022032421390083100_B41","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget."},{"key":"2022032421390083100_B42","doi-asserted-by":"crossref","first-page":"103958","DOI":"10.1016\/j.cellimm.2019.103958","article-title":"TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia","volume":"344","author":"Zhang","year":"2019","journal-title":"Cell Immunol."},{"issue":"4-5","key":"2022032421390083100_B43","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/j.seminoncol.2019.08.005","article-title":"Significance of TIM3 expression in cancer: from biology to the clinic","volume":"46","author":"Solinas","year":"2019","journal-title":"Semin Oncol."},{"key":"2022032421390083100_B44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2018-99-111845","article-title":"Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): preliminary results of a phase I study","volume":"132","author":"Webster","year":"2018","journal-title":"Blood."},{"issue":"7","key":"2022032421390083100_B45","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/bloodadvances.2019000874","article-title":"Blinatumomab consolidation and maintenance therapy in adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia","volume":"4","author":"Rambaldi","year":"2020","journal-title":"Blood Adv."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/12\/1908\/1882230\/bloodbld2021013290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/12\/1908\/1882230\/bloodbld2021013290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:41:08Z","timestamp":1648158068000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/12\/1908\/483090\/Blinatumomab-maintenance-after-allogeneic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021013290","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}